GHENT, Belgium, 19 February 2015 - Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2014 on Thursday 26 February 2015 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2014 will be presented, followed by a Q&A session. This event will be held on Thursday 26 February 2015 at 3.00 pm CET/09.00 am EST.
The conference call will be webcast live and may be accessed on the homepage of the Ablynx website at www.ablynx.com:
http://www.ablynx.com or by clicking here:
http://edge.media-server.com/m/p/f9auo24z. If you would like to participate in the Q&A session, please dial +32 (0)2 404 06 62, confirmation code 9002858. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under the news & events>past events page:
http://www.ablynx.com/en/news-press/past-events-presentations/.
About Ablynx
Ablynx:
http://www.ablynx.com/ is a biopharmaceutical company engaged in the development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes:
http://www.ablynx.com/en/research-development/pipeline/ in development in therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations and significant partnerships with pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com:
http://www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com:
mailto:marieke.vermeersch@ablynx.com%20
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com:
mailto:ablynx@consilium-comms.com
http://hugin.info/137912/R/1895496/672191.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire